Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
Go back to Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.87 +1.11 (0.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $124.30 | 52 Week Low | $71.39 | |||
| Day High | $125.17 | P/E | 68.99 | |||
| Day Low | $123.00 | EPS | $1.81 | |||
| Volume | 8,126,292 | |||||
